期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

吸入糖皮质激素和长效β_2-受体激动剂复方制剂治疗哮喘的研究进展 被引量：12

The progress of inhaled corticosteroid/long-acting β_2-agonist combinations in the treatment of asthma
下载PDF
导出
摘要 联合使用吸入糖皮质激素和长效β2-受体激动剂对控制哮喘的气道炎症和改善气道平滑肌功能具有协同和互补作用。吸入糖皮质激素和长效β2-受体激动剂复方制剂是目前哮喘维持治疗的重要药物,主要包括丙酸氟替卡松/沙美特罗、布地奈德/福莫特罗、二丙酸倍氯松/福莫特罗和糠酸莫米松/福莫特罗等。本文就此类复方制剂在哮喘治疗中的临床地位和研究进展作一概述。 Inhaled corticosteroid/long-actingβ2-agonist （ICS/LABA） combinations play synergic and complementary roles in controlling airway inlfammation and improving the function of airway smooth muscle. They are very important drugs for asthma maintenance. The different combinations of ICS/LABA, such as lfuticasone propionate/salmeterol, budesonide/formoterol, beclomethasones dipropionate/formoterol, mometasone furoate/formoterol, have different pharmacological features. This review summarizes the features and progress of these ICS/LABA in the treatment of asthma.
作者 孙伟 揭志军
机构地区 复旦大学附属上海市第五人民医院呼吸内科
出处 《上海医药》 CAS 2014年第5期3-7,共5页 Shanghai Medical & Pharmaceutical Journal
关键词 哮喘 吸入糖皮质激素 长效Β2-受体激动剂 联合治疗 asthma inhaled corticosteroids long-actingβ2-agonists combination therapy
分类号 R562.25 [医药卫生—呼吸系统]
  • 相关文献

参考文献29

  • 1Levy ML, Thomas M,Small I, et al. Summary of the 2008BTS/SIGN British guideline on the management of asthma[J]. Prim Care Respir J, 2009, 18(Suppl 1); S1-S16. 被引量：1
  • 2Kaur M, Holden NS, Wilson SM, et al. Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents oninflammatory gene expression in human ASM cells: a role forprotein kinase A [J]. Am J Physiol Lung Cell Mol Physiol,2008,295(3): L505-L514. 被引量：1
  • 3Salter M, Biggadike K, Matthews JL, et al. Pharmacologicalproperties of the enhanced-affinity glucocorticoid fluticasonefuroate in vitro and in an in vivo model of respiratoryinflammatory disease [J]. Am J Physiol Lung Cell MolPhysiol, 2007, 293(3): L660-L667. 被引量：1
  • 4Kroegel C, Wirtz H. History of guidelines for the diagnosisand management of asthma: from opinion to control [J].Drugs, 2009,69(9): 1189-1204. 被引量：1
  • 5Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective [J]. J Clin Pharmacol, 2004,44(1): 37-47. 被引量：1
  • 6Derendorf H, Nave R, Drollmann A, et al. Relevanceof pharmacokinetics and pharmacodynamics of inhaledcorticosteroids to asthma [J]. Eur Respir J, 2006, 28(5): 1042-1050. 被引量：1
  • 7Bateman ED, Bousquet J, Keech ML, et al. The correlationbetween asthma control and health status: the GOAL study[J]. Eur Respir J, 2007, 29(1): 56-62. 被引量：1
  • 8Lundback B, Ronmark E, Lindberg A, et al. Asthma controlover 3 years in a real-life study [J]. Respir Med, 2009, 103(3):348-355. 被引量：1
  • 9Pasha MA, Smith TC, Feustel PJ, et al. Effects of low-dosefluticasone propionate/salmeterol combination therapy onexhaled nitric oxide and nitrite/nitrate in breath condensatesfrom patients with mild persistent asthma [J]. J Asthma, 2013,50(1): 64-70. 被引量：1
  • 10Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief inmild-to-moderate asthma: a randomized, double-blind trial[J]. Chest, 2006, 129(2): 246-256. 被引量：1

二级参考文献7

  • 1Kaliner MA. Pharmacologic characteristics and adrenal suppression with newer inhaled corticosteroids: A comparison of ciclesonide and fluticasone propionate [J]. Clin Ther, 2006, 28 (3): 319 -331. 被引量：1
  • 2Newman S, Salmon A, Nave R, et al. High lung deposition of 99roTe -labelled ciclesonide administered via HFA -MDI to patients with asthma [J]. Resp Med, 2006, 100 (3) : 375 -384. 被引量：1
  • 3Niphadkar P, Jagarmath K, Joshi JM, et al. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: A phase Ⅲ, randomized, double - dummy, open - label study [ J ]. Clin Ther, 2005, 27 (11) : 1752 -1763. 被引量：1
  • 4Hansel TT, Benezet O, Kafa H, et al. A multinational, 12 - week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma [J]. Clin Ther, 2006, 28 (6) : 906 - 920. 被引量：1
  • 5Magnussen H, Hofman J, Staneta P, et al. Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma [J]. J Asthma, 2007, 44 (7) : 555 - 563. 被引量：1
  • 6Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma [J]. Pulm Pharmacol Ther, 2006, 19 (6) : 404 -412. 被引量：1
  • 7Lee DK, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high - dose ciclesonide and fluticasone in moderate persistent asthma [J]. Chest, 2005, 127 (3) : 851 -860. 被引量：1

同被引文献126

引证文献12

二级引证文献52

上海医药
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部